Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Adlai Nortye

<< Previous

Bullboard Posts

Next >>

Comment by stayhumble1on Apr 19, 2021 2:23pm

210 Views

Post# 33022991

RE:RE:Adlai Nortye

That is also my understanding Askretka re: Adlai Nortye's Ph3 not having yet begun. As per Adlai's news release Mar 21/2019 concerning their plans for a Ph3 trial: We will launch the clinical trial to join our global partner Oncolytics Biotech Inc. when they initiate their phase III registration study. We will continue to bring more options to cancer patients."

askretka wrote:
I've been on the Website and seen that chart. I don't think Phase 3 has started. There should be an announcement somewhere and I think Oncolytics would get another milestone payment? I'm pretty sure they were waiting for Aware data first.

<< Previous

Bullboard Posts

Next >>

Three micro-cap value stocks trading at peak pessimism